Senhwa Bioscience’s Silmitasertib Received the US FDA IND Approval to treat patients with community-acquired pneumonia (CAP)
Shots:
- The US FDA approved P-II IND evaluating silmitasertib (CX-4945) that aimed to determine if silmitasertib administered early on hinders the development of CAP by preventing the increased production of cytokines linked to the influenza and SARS-CoV-2 viruses
- The drug was previously investigated in 2 investigator-initiated trials that demonstrated therapeutic benefit and faster recovery in individuals with mild COVID-19 symptoms
- Silmitasertib was already granted ODD by the US FDA for Cholangiocarcinoma (2016), Medulloblastoma (2020) & FTD recurrent Sonic Hedgehog-driven Medulloblastoma (2021)
Ref: PR Newswire | Image: Senhwa Bioscience
Related News:- Innoviva Specialty Therapeutics’ Xacduro Receives the US FDA’s Approval for Pneumonia Caused by Acinetobacter
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
